The Motley Fool··Jonathan PoncianoViking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum
ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech